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Background: Depression is one of the major contributors to poorer quality of life amongst individuals with psy-
chosis and schizophrenia. The study was designed as a Pilot Trial to determine the parameters of a larger, deﬁn-
itive pragmaticmulti-centre randomised controlled trial of Acceptance and Commitment Therapy for depression
after psychosis (ACTdp) for individuals with a diagnosis of schizophrenia who also meet diagnostic criteria for
major depression.
Methods: Participants were required tomeet criteria for schizophrenia andmajor depression. Blinded follow-ups
were undertaken at 5-months (end of treatment) and at 10-months (5-months posttreatment). Primary out-
comes were depression asmeasured by the Calgary Depression Scale for Schizophrenia (CDSS) and the Beck De-
pression Inventory (BDI).
Results:A total of 29participantswere randomised toACTdp+Standard Care (SC) (n=15) or SC alone (n=14).
We did not observe signiﬁcant differences between groups on the CDSS total score at 5-months (Coeff=−1.43,
95%CI−5.17, 2.32, p = 0.45) or at 10-months (Coeff = 1.8, 95%CI−2.10, 5.69, p = 0.36). In terms of BDI, we
noted a statistically signiﬁcant effect in favour of ACTdp + SC at 5-months (Coeff = −8.38, 95%CI −15.49,
−1.27, p = 0.02) but not at 10-months (Coeff =−4.85, 95%CI−12.10, 2.39, p = 0.18). We also observed sig-
niﬁcant effects on psychological ﬂexibility at 5-months (Coeff =−8.83, 95%CI−14.94,−2.71, p b 0.01) but not
10-months (Coeff =−4.92, 95%CI−11.09, 1.25, p = 0.11).
Implications: In this ﬁrst RCT of a psychological therapy with depression as the primary outcome, ACT is a prom-
ising intervention for depression in the context of psychosis. A further large-scale deﬁnitive randomised con-
trolled trial is required to determine effectiveness.
Trial registration: ISRCTN: 33306437
© 2016 Published by Elsevier B.V.
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1. Background
Depression contributes to poorer quality of life amongst individuals
with psychosis and schizophrenia (Saarni et al., 2010). Prevalence rates
suggest between 33% and 50% of individuals meet criteria for major
depression (Whitehead et al., 2002; Birchwood et al., 2000). Depression
is associated with greater risk of suicide (Drake et al., 1985), poorer ad-
herence to treatment (Conley, 2009), greater interpersonal problems
(Rocca et al., 2005) and greater insight (Mintz et al., 2003). Shame is
key feature in the emergence of depression (Gumley et al., 2010),
where individuals' envisage a bleak future status, through stigma and
the loss of social, interpersonal and vocational roles (Birchwood et al.,
2000).
There is a lack of robust evidence supporting the use of antidepres-
sant (Whitehead et al., 2002) and psychological (Wykes et al., 2008) in-
terventions for depression in context of schizophrenia. Although there
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is preliminary evidence that depression symptoms improve in people
receiving CBT for psychosis (CBTp) (Wykes et al., 2008) this important
outcome domain is not typically assessed in CBTp trials (Jauhar et al.,
2014) so there is a need to build the treatment evidence base. Accep-
tance and Commitment Therapy (ACT) could offer a promising psycho-
logical intervention that helps reduce unhelpful coping strategies
including rumination and avoidance, and enables commitment to be-
havioural changes consistent with personal values. Randomised con-
trolled trials show that ACT reduces depression in non-psychotic
populations (Hacker et al., 2016).
Previous non-blind randomised controlled trials investigating
ACT for psychosis with rehospitalisation as the primary outcome
have shown therapeutic promise in US acute inpatient settings
(Bach and Hayes, 2002; Gaudiano and Herbert, 2006). Gaudiano
and Herbert (2006) found a small effect of ACT on negative emotion
in people with psychosis. White et al. (2011) investigated ACT for
psychosis with the primary outcome focused on emotional distress.
They found a signiﬁcant difference between the ACT and Treatment
as Usual (TAU) groups for negative symptoms. There was also a
trend on the limit of signiﬁcance for differences between the groups
in depression (p= 0.051) and improvement in depression was asso-
ciated with self-reported increases inmindfulness. In a later analysis,
White et al. (2015) found that ACT was associated with signiﬁcantly
greater likelihood of achieving a clinically signiﬁcant improvement
in depression.
To summarise, feasibility research informed the present study that
(a) ACT could be delivered to outpatientswith psychosis andwas highly
acceptable, (b) that ACT appeared to improve symptoms of depression
and negative symptoms and (c) that improvements in depression
were associated with ACT relevant mechanisms of change (increased
mindfulness skills). Therefore this study was designed as a Pilot Trial
(Craig et al., 2008) to determine the parameters of a larger, deﬁnitive
pragmaticmulti-centre (UKwide) randomised controlled trial of Accep-
tance and Commitment Therapy for depression after psychosis (ACTdp)
for individuals with a diagnosis of schizophrenia who also meet diag-
nostic criteria for major depression. In this manuscript we address the
following questions:
a) What are the potential numbers of participants who fulﬁl eligibility
criteria?
b) What proportion of potential participants provides fully informed
consent to participate in the Trial?
c) What is the overall rate of follow-up in the ﬁrst 5-months and at 10-
months?
d) What proportion of participants engages with ACTdp?
e) What rates of improvement in primary (depression) and secondary
outcomes (Positive and Negative Syndrome Scale and Questionnaire
for Personal Recovery) are observed at 5-month (end of treatment)
follow-up and 10-month follow-up?
f) What are the associations with ACT speciﬁc mechanisms (mindful-
ness skills, psychological ﬂexibility) and outcome in terms of
depression?
2. Methods/design
2.1. Design
The studywas a Parallel group RandomisedOpen Blinded Evaluation
(PROBE) of Acceptance and Commitment Therapy for depression after
psychosis (ACTdp). The study protocol was registered before initiating
recruitment (ISRCTN: 33306437). The protocol was published before
treatment codes were broken and data were analysed (Gumley et al.,
2015). Ethical approval was provided by West of Scotland Research
Ethics Committee (12/WS/0311). Managerial approval was provided
by NHS Greater Glasgow & Clyde (GN11CP470).
2.2. Participants
Participants were consecutively recruited, assessed and randomised.
Inpatients or outpatients, aged 16 or over and receiving (a) anti-psy-
chotic medication (b) psychiatric follow-up and (c) follow-up from a
secondary mental health care community based services. Participants
met DSM-IV-TR criteria for schizophrenia and major depression (con-
ﬁrmed by Structured Clinical Interview for DSM/SCID-I & Calgary De-
pression Scale/CDSS for Schizophrenia; score N 7; Kim et al., 2006).
Individuals with substance use problems were eligible for inclusion
but those with signiﬁcant learning disability, or who were unable to
speak English were not included.
2.3. Entry
Potential participants were identiﬁed by their clinical team or by
self-referral. Following signed informed consent a Research Assistant
(RA) conducted baseline assessments. The Psychosis and Mood Epi-
sodes section of the SCID-I was used to assess diagnostic eligibility.
Inter-rater reliability for the SCID-I was 90% (range 82–100%).
2.4. Randomisation
Eligible participants were randomised following completion of the
baseline assessments. Randomisation (at the individual level) was
organised at the Robertson Centre for Biostatistics, a fully registered
andNIHR approvedUKClinical Trials Unit. Randomisationwas stratiﬁed
for early (b2 years duration) versus established psychosis (N2 years
duration).
2.5. Follow-up
Participants were assessed at entry pre-randomisation, 5 months
and 10-months by a blinded RA. All assessments were audio-recorded
with consent by the participant. Management of blind breaks, inter-
rater reliability and safety reporting were governed by speciﬁcally de-
signed Standard Operating Procedures.
2.6. Protecting the blind
RAs entered participant details via a secure web based portal. Fol-
lowing allocation, another member of the research group received the
outcome of randomisation and informed the participant and their treat-
ment team. Blinding was maintained using a wide range of measures
(e.g. separate ofﬁces for therapists and researchers, protocols for an-
swering phones, message taking and secretarial support, forbidding
any discussions of participants between RAs and therapists following
randomisation, separate diaries and security for electronic
randomisation information).
2.7. Blind breaks
When a blind break occurred, the RA affected informed the Chief In-
vestigator (CI) within twoworking days. In this event a second assessor
(blind, where possible, to the participant's allocation) undertook an in-
dependent rating of the assessment. Following independent rating, as-
sessors met to discuss and resolve any discrepancies. The original
assessor entered agreed ratings into the Case Record Form (CRF).
Where possible, another team member, who remained blind to
randomisation status, completed the remaining assessments for that
participant.
2.8. Inter-rater reliability
Inter-rater reliability meetings were held on a monthly basis. RAs
were trained in all of the study measures before commencing data
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collection. This included observation of a live assessment of psychopa-
thology ratings (PANSS, CDSS, SCID) with an experienced research as-
sessor. Audio recordings were used for ongoing RA training, secondary
assessment when blind breaks occurred, and ﬁdelity checking to detect
and correct rater drift.
2.9. Serious adverse events
In accordance with NIHR trial management standards (Trial
Managers Network, 2014), a Serious Adverse Event (SAE) was deﬁned
as any occurrence that (a) resulted in death, (b) was life threatening,
(c) required hospitalisation or prolongation of existing hospitalisation,
(d) resulted in persistent or signiﬁcant disability or incapacity, or (e)
was considered otherwise medically signiﬁcant by the Chief
Investigator.
2.10. Primary outcomes
The Calgary Depression Scale for Schizophrenia (CDSS, Addington et
al., 1990) assessed severity of depression. The CDSS was better the BDI,
PANSS –Depression subscale, andHAM-D for both sensitivity (94%) and
speciﬁcity (89%) of SCID Depression diagnosis (Kim et al., 2006). Inter-
rater reliability for the CDSS was 92% (range 67–100%). In this study
the Intraclass Correlation Coefﬁcient was ICC = 0.68 (95%CI, 0.46–
0.82). CDSS was also associated with PANSS Emotional Distress (rs =
0.78, 95%CI, 0.67–0.85)
The Beck Depression Scale (BDI-II; Beck et al., 1996) was used as a
well-established self-report measure of depression with excellent reli-
ability and validity. In this study Cronbach's Alpha was α = 0.91
(95%CI, 0.88–0.94). The CDSS and BDI-II were correlated rs = 0.70
(95%CI, 0.56–0.80). This is consistent with Addington et al. (1993)
who found a correlation of rs = 0.69 amongst outpatients with a diag-
nosis of Schizophrenia.
2.11. Therapy mechanisms
The Kentucky Inventory of Mindfulness Skills (KIMS; Baer et al.,
2004) was used to assess four mindfulness skills: observing, describ-
ing, acting with awareness, and accepting without judgement. The
KIMS has good internal consistency, test retest reliability and con-
struct validity. In this study Cronbach's Alpha was α = 0.82
(95%CI, 0.76–0.88).
Psychological ﬂexibility was assessed with the 7 item version of
the Acceptance and Action Questionnaire (AAQ-II; Bond et al.,
2011). This measure has satisfactory structure, reliability, and
validity. In this study Cronbach's Alpha was α= 0.88 (95%CI, 0.84–
0.92).
2.12. Secondary outcomes
The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987)
was used to measure psychiatric symptoms. We adopted the 5-factor
model that yields scores for positive, negative, disorganisation, excite-
ment and emotional distress symptoms (van der Gaag et al., 2006).
Inter-rater reliability for the PANSS in this trial was 83% (range 63–
97%), and the Intraclass Correlation Coefﬁcient was ICC = 0.88 (95%CI,
0.83–0.91).
The Process of Recovery Questionnaire (QPR; Neil et al., 2009) was
used tomeasure service user rated recovery. The QPR has two subscales
measuring intrapersonal tasks and interpersonal factors relevant to per-
sonal recovery and has excellent reliability and validity. In this study
Cronbach's Alpha was α= 0.93 (95%CI, 0.91–0.95).
2.13. Treatments
2.13.1. Acceptance and Commitment Therapy for depression after psychosis
(ACTdp)
Individuals received up to 5 months of individual ACTdp. ACTdp is
based on the rationale that the experience of psychosis can threaten
progress in valued life domains. The ACTdp intervention protocol was
used to enhance engagement with valued life activities through values
clariﬁcation, increasing mindfulness and psychological ﬂexibility and
reducing experiential avoidance and fusion with experiences. An indi-
vidual formulation based on the six ACT core processes was developed
for each participant in the treatment arm. Fidelity of treatment strategy
use and consistency with the ACT model were determined via weekly
supervision by a senior clinician. The details of intervention have been
described in greater detail elsewhere (Gumley et al., 2015; White,
2015).
2.13.2. Standard Care (SC)
Treatment received by all participants in the trial was examined in
order to establish the parameters of Standard Care. For inclusion, all par-
ticipants had to be in receipt of antipsychotic medication and follow-up
from a secondary specialist mental health service.
2.14. Statistical analyses
As a pilot study we aimed to assess the variability in the outcome
data and look for suggestive trends in order to estimate parameters
for a deﬁnitive multi-site RCT. To this end, we planned exploratory re-
peatedmeasures regressionmodels, adjusting for baselinemeasures in-
cluding the stratiﬁcation variable to be ﬁtted to assess treatment effects
on themain outcomemeasures and the evolution of these treatment ef-
fects over time and to estimate residual variability.We aimed to explore
outcome measures for strong treatment signals. Therefore we report
both ITT and Per Protocol Sample (PPS).
3. Results
3.1. Population
Theﬂowof participants into the study is described in Fig. 1.We iden-
tiﬁed 92 potential participants of whom 55 were referred to the study.
Of this group, 38 gave their informed consent to enter the study and 7
were not eligible. Two participants, who initially gave their informed
consent subsequently changed their mind before randomization. This
left 29 participants who were fully assessed before being randomised
to ACTdp + SC (n = 15) or SC alone (n = 14). In terms of follow-up
of ACTdp + SC, two participants declined follow-up at 5-months and
we were unable to follow-up 1 further participant at 10-months. In
SC, 1 participant declined follow-up at 10-months.
The characteristics of theﬁnal sample are described in Table 1 below.
The samplewere on average 46.5 years old, male (n=19, 65.5%), white
Scottish (n = 27, 93.1%) with on average 13.2 years of education.
During the trial we observed 7 Serious Adverse Events (SAEs). All
SAEs were related to Hospitalisation, 2 (28.6%) were in the
ACTdp + SC group and 5 (71.4%) in the SC group. There were 14
unblindings during the trial. Of these 11 (78.6%) were in the
ACTdp + SC group and 3 (21.4%) were in SC. All unblindings were
rated by another Researcher masked to treatment allocation and subse-
quent follow-ups were blind rated.
3.2. Intervention
On average 17.4 (s.d. = 5.9) ACTdp sessions were scheduled, and
15.4 (s.d. = 6.2) were attended by participants. Of the remaining ses-
sions, 0.7 (s.d. = 1.4) were cancelled and 1.2 (s.d. = 1.5) not attended.
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TOTAL REFERRALS
N = 55
CONSENTED
N = 38
Declined Consent n = 12
Unable to contact n = 4
Not eligible n = 1
RANDOMISED
N = 29
Not eligible n = 7
Declined to proceed n = 2
Standard Care
Baseline
N = 14
ACTdp
Baseline
N = 15
ACTdp
5 Months
N = 13
N = 2 declined
Standard Care
5 Months
N = 14
ACTdp
10 Months
N = 12
N =1 lost to follow up
Standard Care
10 Months
N = 13
N = 1 declined
Fig. 1. Adapt consort diagram.
Table 1
Demographic characteristics of sample.
Variable Statistic Full ITT (N = 29) Standard Care (N = 14)
ACTdp + SC
(N = 15)
Age (Years) Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Mean (SD) 46.5 (9.0) 46.2 (8.9) 46.8 (9.3)
Gender Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Male N (%) 19 (65.5%) 9 (64.3%) 10 (66.7%)
Ethnicity Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
White N (%) 27 (93.1%) 12 (85.7%) 15 (100.0%)
Black minority ethnic N (%) 2 (6.9%) 2 (14.3%) 0 (0.0%)
Years of education Nobs (Nmiss) 28 (1) 13 (1) 15 (0)
Mean (SD) 13.2 (4.2) 14.0 (4.9) 12.5 (3.4)
Highest education Nobs (Nmiss) 27 (2) 13 (1) 14 (1)
Primary or less N (%) 4 (14.8%) 2 (15.4%) 2 (14.3%)
Secondary N (%) 9 (33.3%) 3 (23.1%) 6 (42.9%)
Tertiary/further N (%) 13 (48.1%) 7 (53.8%) 6 (42.9%)
Other general N (%) 1 (3.7%) 1 (7.7%) 0 (0.0%)
Not known N (%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
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The number of participants attending 10 or more sessions (our a priori
deﬁnition of an adequate number of sessions) was 10 (71.4%).
3.3. Outcomes
The outcomes of depression measured by CDSS and BDI are de-
scribed in Table 2 below. We did not observe signiﬁcant differences be-
tween groups on the CDSS total score at 5-months (Coeff = −1.43,
95%CI −5.17, 2.32, p = 0.45) or at 10-months (Coeff = 1.8, 95%CI
−2.10, 5.69, p=0.36). Outcomes Per Protocol Sample (PPS) did not dif-
fer from ITT analysis. In terms of BDI, we noted a statistically signiﬁcant
effect in favour of ACTdp + SC at 5-months (Coeff =−8.38, 95%CI−
15.49,−1.27, p = 0.02) but not at 10-months (Coeff =−4.85, 95%CI
−12.10, 2.39, p = 0.18). In the PPS analyses we noted sustained out-
comes in favour of ACTdp + SC at both 5-months (Coeff = −10.18,
95%CI −17.69, −2.68, p = 0.01) and 10-months (Coeff = −8.11,
95%CI−15.62,−0.60, p = 0.04).
The outcomes for AAQ and KIMS are described in Table 3. We ob-
served a signiﬁcant effect in favour of ACTdp+ SC in terms of improved
psychological ﬂexibility (reduced AAQ score) at 5-months follow-up
(Coeff=−0.883, 95%CI−14.94,−2.71, p b 0.01) but not at 10-months
(Coeff =−4.92, 95%CI−11.09, 1.25, p= 0.11). In the PPS analysis out-
comes at 5-months (Coeff =−10.71, 95%CI−16.16,−5.26, p b 0.01)
and 10-months (Coeff =−6.27, 95%CI−11.72,−0.82, p = 0.03).
In terms of KIMS subscales we observed the following outcome sig-
nals. At 10-months signiﬁcant outcomes in favour of ACTdp + SC were
noted for KIMSObserving (Coeff=4.94, 95%CI 0.47, 9.41, p=0.03) and
KIMS Total (Coeff= 10.91, 95%CI 0.22, 21.60, p=0.05). In the PPS anal-
ysis signiﬁcant effects in favour of ACTdp + SC were noted for KIMS
Accepting at 5-months (Coeff = 4.78, 95%CI 0.68, 8.88, p = 0.02) and
10-months (Coeff = 5.39, 95%CI 1.29, 9.40, p = 0.01) and KIMS Total
at 5-months (Coeff= 9.44, 95%CI 0.07, 18.82, p= 0.05) and 10-months
(Coeff = 12.63, 95%CI 3.25, 22.00, p = 0.01).
3.4. Secondary outcomes
We did not observe any other effects on outcomes using the Ques-
tionnaire for Personal Recovery and the Positive and Negative Syn-
drome Scale with one exception which was that there was a
signiﬁcant effect in favour of ACTdp + SC on PANSS Cognitive
Disorganisation (Coeff =−4.92, 95%CI−8.50,−1.35, p = 0.01) and
PANSS Excitement at 5-months (Coeff = 1.98, 95%CI −3.60, −0.35,
p = 0.019). In the PPS analyses we noted signiﬁcant effects in favour
of ACTdp + SC for PANSS Negative (Coeff = −4.03, 95%CI −7.77,
−0.28 p = 0.04), PANSS Cognitive Disorganisation (Coeff = −6.16,
95%CI −10.01, −2.30, p = 0.003), PANSS Emotional Distress
(Coeff = −2.46, 95%CI −4.74, −0.18, p = 0.04) and PANSS Total
(Coeff =−12.45, 95%CI−23.11,−1.80, p = 0.02) at 5-months.
Table 2
Primary outcomes at baseline, 5-months and 10-months.
Variable Statistic ITT (N = 29) SC (N = 14)
ACTdp + SC
(N = 15)
Calgary Depression Scale - Baseline Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Mean (SD) 14.0 (4.9) 15.0 (5.8) 13.1 (4.0)
Calgary Depression Scale - 5-months Nobs (Nmiss) 27 (2) 14 (0) 13 (2)
Mean (SD) 10.2 (6.1) 12.0 (6.6) 8.3 (5.0)
Calgary Depression Scale - 10-months Nobs (Nmiss) 25 (4) 13 (1) 12 (3)
Mean (SD) 9.5 (5.9) 10.0 (6.5) 9.0 (5.3)
Beck Depression Inventory - baseline Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Mean (SD) 31.7 (12.6) 29.9 (14.3) 33.3 (11.1)
Beck Depression Inventory - 5-months Nobs (Nmiss) 27 (2) 14 (0) 13 (2)
Mean (SD) 21.9 (10.5) 25.2 (11.3) 18.4 (8.7)
Beck Depression Inventory - 10-months Nobs (Nmiss) 25 (4) 13 (1) 12 (3)
Mean (SD) 23.5 (14.3) 25.7 (14.3) 21.2 (14.6)
Table 3
Therapy speciﬁc measures at baseline, 5-months and 10-months.
Variable Statistic ITT (N = 29) SC (N = 14)
ACTdp + SC
(N = 15)
AAQ - baseline Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Mean (SD) 34.8 (7.4) 34.4 (9.5) 35.2 (5.1)
AAQ - 5-months Nobs (Nmiss) 27 (2) 14 (0) 13 (2)
Mean (SD) 32.5 (10.6) 36.4 (10.2) 28.3 (9.7)
AAQ - 10-months Nobs (Nmiss) 25 (4) 13 (1) 12 (3)
Mean (SD) 32.1 (10.3) 33.8 (9.4) 30.2 (11.3)
KIMS Observing Baseline Nobs (Nmiss) 29 (0) 14 (0) 15 (0)
Mean (SD) 36.0 (8.2) 39.4 (7.7) 32.8 (7.5)
KIMS Observing 5-months Nobs (Nmiss) 27 (2) 14 (0) 13 (2)
Mean (SD) 36.7 (8.1) 37.1 (8.8) 36.4 (7.8)
KIMS Observing 10-months Nobs (Nmiss) 25 (4) 13 (1) 12 (3)
Mean (SD) 39.9 (7.3) 39.3 (8.4) 40.6 (6.3)
KIMS Describing Baseline Mean (SD) 21.6 (6.0) 22.8 (7.3) 20.5 (4.6)
KIMS Describing 5-months Mean (SD) 22.9 (5.7) 22.8 (6.4) 23.0 (5.1)
KIMS Describing 10-months Mean (SD) 24.6 (5.7) 24.1 (7.0) 25.2 (4.0)
KIMS Awareness Baseline Mean (SD) 26.1 (6.0) 27.2 (6.0) 25.0 (5.9)
KIMS Awareness 5-months Mean (SD) 27.1 (6.3) 27.9 (7.1) 26.4 (5.5)
KIMS Awareness 10-months Mean (SD) 26.6 (6.1) 26.5 (5.8) 26.7 (6.7)
KIMS Accepting Baseline Mean (SD) 23.8 (7.1) 23.6 (8.4) 24.0 (6.0)
KIMS Accepting 5-months Mean (SD) 25.0 (6.9) 23.8 (7.3) 26.3 (6.4)
KIMS Accepting 10-months Mean (SD) 24.7 (7.2) 22.6 (7.1) 27.0 (6.8)
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3.5. Mechanisms of change
In order to investigate hypothesized mechanisms of change we cal-
culated change scores at 5-months and 10-months for the CDSS, BDI,
KIMS and AAQ. We then investigated associations between changes in
depression and changes in mindfulness and psychological ﬂexibility.
Table 4 below summarizes the observed correlations at 5-months and
10-months. Consistentwith the lack of observed effects on CDSSwe ob-
served no signiﬁcant associations between depression and hypothe-
sized mechanisms of change at either 5 or 10-months. With respect to
changes in BDI we observed signiﬁcant correlations with changes in
psychological ﬂexibility at 5-months (r=0.54, p b 0.01) and 10-months
(r= 0.41, p= 0.04). Furthermore, we observed signiﬁcant associations
between KIMS Observing (r = −0.58, p b 0.01), KIMS Describing
(r = −0.63, p b 0.01), KIMS Awareness (r = −0.41, p = 0.03) and
change in BDI at 5-months. Finally we observed as signiﬁcant associa-
tion between KIMS Describing (r=−0.49, p = 0.01), KIMS Awareness
(r = −0.53, p b 0.01), KIMS Acceptance (r = −0.49, p = 0.01) and
change in BDI at 10-months.
4. Discussion
This is theﬁrst randomised controlled trial of any psychological ther-
apy in psychosis that speciﬁed depression as a primary outcome. We
sought to map the parameters for a larger scale deﬁnitive trial of ACT
for depression after psychosis. Our primary concern was the identiﬁca-
tion of outcome signals in relation to depression (CDSS, BDI-II), and
established therapy mechanisms (KIMS and AAQ) as a basis to estimate
the power and sample size requirements for a future trial. Over a period
of 12-months recruitment, we received 92 potential enquiries,
converting to 55 participant referrals (referrals 4.6 per month) leading
to 29 (2.4 per month) randomisations. Over 10-months we retained
25 (86.3%) of participants in follow-up.
One of the key challenges for the studywas the identiﬁcation and re-
cruitment of potential participants. Depression co-occurring with psy-
chosis was not routinely identiﬁed by mental health staff. Positive
symptoms tended to be prioritised for monitoring and assessment,
therewas poor discrimination between negative symptomsanddepres-
sion, potential participants rarely reported depressedmood (despite se-
vere symptomson theBDI-II), and conversations about depressedmood
and hopelessness were frequently avoided. In a future large-scale trial,
supporting mental health staff with knowledge and skills to detect
and respond to depression in this group would increase recruitment.
Our results also point to the need to develop pathways to enhance
self-referral for the assessment and treatment of depression. This is par-
ticularly important given the role of depression in reduced quality of life
and serious adverse outcomes such as death by suicide (Foster, 2015;
Pompili et al., 2008).
The ACTdp intervention was well tolerated. On average participants
received 15 sessions over 5-months, rates of cancellation and non-at-
tendance were low and 70% received at least 10-sessions of therapy.
Although the studywas not powered or designed as an efﬁcacy or ef-
fectiveness trial we did wish to explore treatment signals and we had
established a priori primary outcomes, therapy speciﬁc outcomes, and
secondary outcomes. We did not observe any change signals on the
CDSS. We noted a statistically signiﬁcant improvement in BDI-II for
the ACTdp + SC group at 5-months but not at 10-months. We noted a
between group Cohen's Effect Size of r = 0.67 at 5-months end of treat-
ment and r=0.31 at 10-months. These effects comparewell with those
identiﬁed in a recentmeta-analysis (Hacker et al., 2016)who found that
studies investigating ACT for depression as a primary treatment target
(n = 12 studies comprising n = 674 participants) suggested also
large signiﬁcant between group effect size (d = 0.73, p b 0.001). For
ACT versus active control conditions (n = 15 studies comprising n =
755 participants) ﬁndings suggested a small non-signiﬁcant between
groups effect size (d = 0.26, n.s.).
The different patterns of depression change scores on the observer-
rated versus self-report measures have potential implications for future
trials. First, the effect size for depression reduction on the CDSS for the
ACT + SC care group was d = 0.30 at the 5 month end of treatment
time-point and d =−0.15 at the 10 month post treatment follow-up
suggesting that the CDSS detected smaller effects. Second, we noted a
lower than expected ICC=0.68 for the CDSS and thismay have contrib-
uted to some inconsistency of outcomes. Given, the pilot nature of this
study, it is difﬁcult to drawﬁrm conclusions regarding the inconsistency
of these outcomes and therefore the CDSS should be retained in a future
main trial. However, since service userswith psychosis express a prefer-
ence for self-reportmeasures as primary trial outcomes (Crawford et al.,
2011), any future RCT following from this pilot could justify being
powered to detect an effect on the BDI-II.
Consistent with the model of therapeutic change in ACT and with
earlier observations (White et al., 2011, 2013) we observed statistically
signiﬁcant changes in psychological ﬂexibility and mindfulness. We
noted signiﬁcant associations between psychological ﬂexibility at both
5 and 10-month follow-up using the BDI and associations between
changes in mindfulness and depression at 5 and 10-month follow-up.
Given this replication of earlier ﬁndings we propose that the strongest
signals in relation to ACTdp relate to measures of self reported depres-
sion, psychological ﬂexibility and mindfulness. Although lack of change
in objectivemeasures of symptom severity have been reported in previ-
ous trials of ACTp (e.g. Bach and Hayes, 2002) lack of any signal on any
observer based measures in our study is an important consideration.
We would also argue for the additional inclusion of behaviourally
based measures of functioning. This would be in keeping with the
goals of ACTdp to increase behavioural activation through engagement
in valued activities. A future large-scale trial could include themeasure-
ment of daily activities as a key outcome. In their trial of Social Recovery
CBT (CBTsr) in ﬁrst episode psychosis, Fowler et al. (2009) used the
Time Use Survey (Short, 2006) as an interview based measure of
hours spent in ‘Constructive Economic Activity’ and in ‘Structured Activ-
ity’. The pilot study data showed signals suggesting that compared to
TAU CBTsr was associated with improved economic activity (increase
of 4.4 h versus 3.2 h) and improved structured activity (12.0 h versus
4.1 h). These measures can also be supplemented by use of objective
measures of physical activity such as ActiGraphy. For example, using
actigraphic measurement of daytime routines Wichniak et al. (2011)
found that in people with schizophrenia, higher rates of depression
were associated with lower rates of physical activity and longer time
spent in bed. This is a highly relevant outcome as a lack of physical
and leisure time activity is linked to poorer quality of life in schizophre-
nia (Vancampfort et al., 2011).
Our study had some noteworthy limitations. First, the sample size of
29 was small. But, the 11 randomised controlled trials included in the
Whitehead et al. (2002) Cochrane Review of antidepressants in schizo-
phrenia all randomised n b 30 participants. Of the 5 RCTs of ACTp (Bach
and Hayes, 2002; Gaudiano and Herbert, 2006; White et al., 2011;
Shawyer et al., 2007; Gaudiano et al., 2015) the mean sample size is
Table 4
Associations between primary outcomes (change scores CDSS and BDI) and therapy
mechanisms (and respective change scores KIMS and AAQ).
Variable
KIMS
Observing
KIMS
Describing
KIMS
Awareness
KIMS
Acceptance
AAQ
total
CDSS
5-months
−0.11 −0.34 −0.14 −0.31 0.30
CDSS
10-months
0.06 −0.33 −0.26 −0.33 0.28
BDI
5-months
−0.58⁎⁎ −0.63⁎⁎ −0.41⁎⁎ −0.21 0.55⁎⁎
BDI
10-months
−0.17 −0.49⁎⁎ −0.53⁎⁎ −0.49⁎⁎ 0.41⁎
⁎ p b 0.05.
⁎⁎ p b 0.01.
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40.6 (range 13–80). Gaudiano et al. (2015) conducted a randomised
controlled trial of an ACT based treatment package for people with af-
fective psychoses (mostly major depression with psychotic features)
and foundmedium to large effects for of ACT on depression and psycho-
social functioning. The study sample size was n = 13, randomization
was not independent of trial team and assessment of outcome was un-
blinded. Taken together these ﬁndings indicate a need for large scale,
well-designed methodologically rigorous trials targeting depression in
the context of psychosis. A second limitation is that although our trial
was blinded, our rates of unblinding were high in the ACTdp + SC
group. Our RAs were instructed to remind both staff and participants
about the importance of blinding. In addition, separate ofﬁce facilities,
an independent randomization procedure that protected the blind, ban-
ning discussions regarding participants between RAs and Trial Thera-
pists were instituted throughout the trial. Despite these efforts, the
main source of unblindings was participants and less frequently health
service staff. Where an unblinding occurred we were able to allocate an
alternative blinded researcher to undertake subsequent follow-up as-
sessments. In addition, since all assessments were audio recorded
(with consent) we were able to subject unblinded assessments to inde-
pendent veriﬁcation of symptoms severity. Finally, our approach to re-
cruitment was informed by an earlier feasibility trial of ACT for
emotional distress in psychosis (White et al., 2011). A clear signal
emerging from the trial was a change in depression amongst those par-
ticipants receiving ACT (White et al., 2013, 2015). All of these steps sug-
gest that the observed treatment effect on the self-report BDI-II cannot
be easily dismissed as a spurious consequence of unblinding. Similarly,
the probability that the insigniﬁcant effect on the CDSSwas due to inad-
vertent contamination of observer ratings is reduced by the steps taken
to dealwith unblindings. Themain conclusion to drawabout this relates
to the importance of future trials having a very robust a priori plan for
minimizing the likelihood of penetration of blind treatment allocation.
This is a particular challenge in psychological treatment studies where
therapy content may “leak” through in the accounts given by patients
to research assessors. For example, ACTdp treated patientsmay inadver-
tently report values consistent behavior that has arisen as a conse-
quence of receiving treatment.
Depression is a major contributor to loss of quality of life in schizo-
phrenia and other psychotic disorders (Saarni et al., 2010) and is a
clear risk factor for suicide (Drake et al., 1985). Depression has been as-
sociatedwith poorer adherence to treatment (Conley, 2009), longer du-
ration of untreated psychosis (Drake et al., 2003), greater problems in
family relationships (Rocca et al., 2005), poorer interpersonal function-
ing (Rocca et al., 2005), and greater experiences of stigma (Angermeyer
et al., 2004). The development of future large scale generalizable
randomised controlled trials to improve depression and functioning in
people with schizophrenia and other psychoses is clearly merited. ACT
is one clear candidate treatment that has the potential to improve en-
gagement with valued life goals and activities alongside feelings of de-
pression and demoralization.
Contributors
AG was Chief Investigator, RW supervised the therapists, RW, AB, IF and HMcL were
Principal Investigators, CS, SB, JMcT, and CC recruited participants and undertook assess-
ments, RMacL & EL delivered the experimental interventions, SB, BSR and RY undertook
statistical analyses of the data. All authors contributed to the writing of the manuscript.
Role of funding source
The authors acknowledge the ﬁnancial support of NHS Research Scotland (NRS),
through The Chief Scientist Ofﬁce (CZH/4/743), NHS Greater Glasgow & Clyde
(GN11CP470) and of the Scottish Mental Health Research Network. The research project
was adopted and supported by the Scottish Mental Health Research Network.
Conﬂict of interests
None.
Acknowledgements
We would like to acknowledge the support of participants, their
families and health service staff in supporting the ADAPT trial.
References
Addington, D., Addington, J., Schissel, B., 1990. A depression rating scale for schizo-
phrenics. Schizophr. Res. 3 (4):247–251. http://dx.doi.org/10.1016/j.schres.2013.12.
014.
Addington, D., Addington, J., Maticka-Tyndale, E., 1993. Rating depression in schizophre-
nia: a comparison of a self-report and an observer-report scale. J. Nerv. Ment. Dis. 181
(9), 561–565.
Angermeyer, M.C., Matshinger, H., Corrigan, P.W., 2004. Familiarity with mental illness
and social distance from people with schizophrenia and major depression: testing a
model using data from a representative population survey. Schizophr. Res. 69 (1–
2), 175–182.
Bach, P., Hayes, S.C., 2002. The use of acceptance and commitment therapy to prevent the
rehospitalization of psychotic patients: a randomized controlled trial. J. Consult. Clin.
Psychol. 70 (5):1129–1139. http://dx.doi.org/10.1037/0022-006X.70.5.1129.
Baer, R.A., Smith, G.T., Lykins, E., Button, D., Krietemeyer, J., Sauer, S., Walsh, E., Duggan, D.,
Williams, J.M.G., 2004. Construct validity of the ﬁve facet mindfulness questionnaire
in meditating and nonmeditating samples. Assessment 15 (3):329. http://dx.doi.org/
10.1177/1073191107313003.
Beck, A.T., Steer, R.A., Brown, G.K., 1996.Manual for the Beck Depression Inventory-II. Psy-
chological Corporation, San Antonio.
Birchwood, M.J., Iqbal, Z., Chadwick, P., Trower, P., 2000. Cognitive approach to depression
and suicidal thinking in psychosis. Br. J. Psychiatry 177:516–528. http://dx.doi.org/10.
1192/bjp.177.6.522.
Bond, F.W., Hayes, S.C., Baer, R.A., Carpenter, K.M., Guenole, N., Orcutt, H.K., Waltz, T.,
Zettle, R.D., 2011. Preliminary psychometric properties of the Acceptance and Action
Questionnaire - II: a revised measure of psychological ﬂexibility and experiential
avoidance. Behav. Ther. 42 (4):676–688. http://dx.doi.org/10.1016/j.beth.2011.03.
007.
Conley, R.R., 2009. The burden of depressive symptoms in people with schizophrenia.
Psychiatr. Clin. North. Am. 32 (4):853–861. http://dx.doi.org/10.1016/j.psc.2009.09.
001.
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., Petticrew, M., 2008. Developing
and evaluating complex interventions: the new Medical Research Council guidance.
Br. Med. J. 337:a1655. http://dx.doi.org/10.1136/bmj.a1655.
Crawford, M.J., Robotham, D., Thana, L., Patterson, S., Weaver, T., Barber, R., Wykes, T.,
Rose, D., 2011. Selecting outcome measures in mental health: the views of service
users. J. Ment. Health 20 (4):336–346. http://dx.doi.org/10.3109/09638237.2011.
577114.
Drake, R.,Whitaker, A., Gates, C., Cotton, P., 1985. Suicide among schizophrenics: a review.
Compr. Psychiatry 26 (1):90–100. http://dx.doi.org/10.1016/0010-440X(85)90053-
7.
Drake, R.J., Pickles, A., Nentall, R., Kinderman, P., Haddock, G., Tarrier, N., Lewis, S.W., 2003.
The evolution of insight, paranoia and depression during early schizophrenia.
Psychol. Med. 34 (2):285–292. http://dx.doi.org/10.1016/j.psychres.2005.10.002.
Foster, T., 2015. Schizophrenia and bipolar disorder: no recovery without suicide preven-
tion. Br. J. Psychiatry 207 (5):371–372. http://dx.doi.org/10.1192/bjp.bp.115.165944.
Fowler, D., Hodgekins, J., Painter, M., Reilly, T., Crane, C., Macmillan, I., Mugford, M.,
Croudace, T., Jones, P.B., 2009. Cognitive behaviour therapy for improving social re-
covery in psychosis: a report from the ISREP MRC trial platform study improving so-
cial recovery in early psychosis. Psychol. Med. 39:1627–1636. http://dx.doi.org/10.
1017/S0033291709005467.
Gaudiano, B.A., Herbert, J.D., 2006. Acute treatment of inpatients with psychotic symp-
toms using Acceptance and Commitment Therapy: pilot results. Behav. Res. Ther.
44 (3):415–437. http://dx.doi.org/10.1016/j.brat.2005.02.007.
Gaudiano, B.A., Busch, A.M., Wenze, S.J., Nowlan, K., Eptein-Lubow, G., Miller, I.W., 2015.
Acceptance-based Behaviour Therapy for depression with psychosis: results from a
feasibility randomized controlled trial. J. Psychiatr. Pract. 21 (5), 320–333.
Gumley, A.I., Braehler, C., Laithwaite, H., Macbeth, A., Gilbert, P.A., 2010. Compassion fo-
cused model of recovery after psychosis. Int. J. Cogn. Psychotherapy 3 (2):186–201.
http://dx.doi.org/10.1521/ijct.2010.3.2.186.
Gumley, A.I., White, R.G., Briggs, A., Ford, I., Barry, S., Stewart, C., Beedie, S., Clarke, C.,
Macleod, R., Lidstone, E., Nam, J., McLeod, H., 2015. A parallel group randomized
open blinded evaluation of Accept and and Commitment Therapy for Depression
after psychosis: a pilot trial protocol (ADAPT). Psychosis 8 (2):143–155. http://dx.
doi.org/10.1080/17522439.2015.1100669.
Hacker, T., Stone, P., Macbeth, A., 2016. Acceptance and Commitment Therapy – Do we
know enough? A sequential meta-analysis of randomized controlled trials. J. Affect.
Disord. 15:551–565. http://dx.doi.org/10.1016/j.jad.2015.10.053.
Jauhar, S., McKenna, P.J., Radua, J., Fung, E., Salvador, R., Laws, K.R., 2014. Cognitive-behav-
ioural therapy for the symptoms of schizophrenia: systematic review andmeta-anal-
ysis with examination of potential bias. Br. J. Psychiatry 204 (1):20–29. http://dx.doi.
org/10.1192/bjp.bp.112.116285.
Kay, S., Fiszbein, A., Opler, L., 1987. The Positive and Negative Syndrome Scale (PANSS) for
schizophrenia. Schizophr. Bull. 13 (2):262–276. http://dx.doi.org/10.1093/schbul/13.
2.261.
Kim, S.W., Kim, S.-J., Yoon, B.-H., Kim, J.-M., Hwang, M., Yoon, J.-S., 2006. Diagnostic valid-
ity of assessment scales for depression in patients with schizophrenia. Psychiatry Res.
144 (1):57–63. http://dx.doi.org/10.1016/j.psychres.2005.10.002.
Mintz, A.R., Dobson, K.S., Romney, D.M., 2003. Insight in schizophrenia: a meta-analysis.
Schizophr. Res. 61 (1):75–88. http://dx.doi.org/10.1016/S0920-9964(02)00316-X.
7A. Gumley et al. / Schizophrenia Research xxx (2016) xxx–xxx
Please cite this article as: Gumley, A., et al., A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for
depression after psychosis: Pilot tri..., Schizophr. Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.026
Neil, S., Pitt, L., Kilbride, M., Welford, M., Nothard, S., Sellwood, W., Morrison, T., 2009. The
questionnaire about the process of recovery (QPR): a measurement tool developed in
collaboration with service users. Psychosis 1 (2):145–155. http://dx.doi.org/10.1080/
17522430902913450.
Pompili, M., Lester, D., Innamorati, M., Tatarelli, R., Girardi, P., 2008. Assessment and treat-
ment of suicide risk in schizophrenia. Expert. Rev. Neurother. 8 (1):51–74. http://dx.
doi.org/10.1586/14737175.8.1.51.
Rocca, P., Bellino, S., Calvarese, P., Marchiaro, L., Patria, L., Rasetti, R., Bogetto, F., 2005. De-
pressive and negative symptoms in schizophrenia: different effects on clinical fea-
tures. Compr. Psychiatry 46 (4):304–310. http://dx.doi.org/10.1016/j.comppsych.
2004.09.001.
Saarni, S.I., Viertiö, S., Perälä, J., Koskinen, S., Lönnqvist, J., Suvisaari, J., 2010. Quality of life
of people with schizophrenia, bipolar disorder and other psychotic disorders. Br.
J. Psychiatry 197 (5):386–394. http://dx.doi.org/10.1192/bjp.bp.109.076489.
Shawyer, F., Ratcliffe, K., Mackinnon, A., Farhall, J., Hayes, S.C., Copolov, D., 2007. The
voices acceptance and action scale (VAAS): pilot data. J. Clin. Psychol. 63 (6):
593–606. http://dx.doi.org/10.1002/jclp.20366.
Short, S., 2006. Review of the UK 2000 Time Use Survey. Ofﬁce for National Statistics,
London.
Trial Managers Network, 2014. A Guide to Efﬁcient Trial Management. National Institute
for Health Research, pp. 1–76.
van der Gaag, M., Hoffman, T., Remijsen, M., Hijman, R., de Haan, L., van Meijel, B., van
Harten, P.N., Valmaggia, L., de Hart, M., Cuipers, A., Wiersma, D., 2006. The ﬁve-factor
model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a
revised model. Schizophr. Res. 85 (1–3):280–287. http://dx.doi.org/10.1016/j.schres.
2006.03.021.
Vancampfort, D., Probst, M., Schweewe, T., Maurissen, K., Sweers, K., Knapen, J., De Hart,
M., 2011. Lack of physical activity during leisure time contributes to an impaired
health related quality of life in patients with schizophrenia. Schizophr. Res. 129 (2–
3):122–127. http://dx.doi.org/10.1016/j.schres.2011.03.018.
White, R.G., 2015. Treating depression in psychosis: self-compassion as a valued life direc-
tion. In: Gaudiano, B.A. (Ed.), Incorporating Acceptance and Mindfulness Into the
Treatment of Psychosis: Current Trends and Future Directions. Oxford University
Press, Oxford. ISBN: 9780199997213, pp. 81–107.
White, R.G., Gumley, A.I., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., Mitchell, G.,
2011. A feasibility study of Acceptance and Commitment Therapy for emotional dys-
function following psychosis. Behav. Res. Ther. 49 (12):901–907. http://dx.doi.org/10.
1016/j.brat.2011.09.003.
White, R.G., Gumley, A.I., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., Mitchell, G.,
2013. Depression and anxiety following psychosis: associations with mindfulness
and psychological ﬂexibility. Behav. Cogn. Psychother. 41 (1):34–51. http://dx.doi.
org/10.1017/S1352465812000239.
White, R.G., Gumley, A.I., McTaggart, J., Rattrie, L., McConville, D., Cleare, S., McLeod, H.J.,
Mitchell, G., 2015. Acceptance and commitment therapy for depression following
psychosis: an examination of clinically signiﬁcant change. J Contextual Behav. Sci. 4
(3):203–209. http://dx.doi.org/10.1016/j.jcbs.2015.06.004.
Whitehead, C., Moss, S., Cardno, A., Lewis, G., Furtado, V.A., 2002. Antidepressants for peo-
ple with both schizophrenia and depression. Cochrane Database Syst. Rev. 2
(CD002305). http://dx.doi.org/10.1002/14651858.CD002305.
Wichniak, A., Skowerska, A., Chonjnacka-Wojtowicz, J., Taﬂinski, T., Wierzbicka, A.,
Jernajczyk,W., Jerema, M., 2011. Actigraphic monitoring of activity and rest in schizo-
phrenic patients treated with olanzepine or risperidone. J. Psychiatr. Res. 45 (10):
1381–1386. http://dx.doi.org/10.1016/j.jpsychires.2011.05.009.
Wykes, T., Steel, C., Everitt, B., Tarrier, N., 2008. Cognitive behavior therapy for schizophre-
nia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 34 (3):
523–537. http://dx.doi.org/10.1093/schbul/sbm114.
8 A. Gumley et al. / Schizophrenia Research xxx (2016) xxx–xxx
Please cite this article as: Gumley, A., et al., A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for
depression after psychosis: Pilot tri..., Schizophr. Res. (2016), http://dx.doi.org/10.1016/j.schres.2016.11.026
